Get Premium to unlock powerful stock data
NAS:XFOR (USA)  
X4 Pharmaceuticals Inc logo

X4 Pharmaceuticals Inc

$ 1.04 +0.075 (+7.77%) 08:08 PM EST
P/E:
At Loss
P/B:
0.64
Market Cap:
$ 32.06M
Enterprise V:
$ 4.45M
Volume:
3.04M
Avg Vol (2M):
210.72K
Also Trade In:
Volume:
3.04M
Market Cap $:
32.06M
PE Ratio:
At Loss
Avg Vol (2-Month):
210.72K
Enterprise Value $:
4.45M
PB Ratio:
0.64
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

X4 Pharmaceuticals Inc
NAICS : 325412 SIC : 2836
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
Description
X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.
Name Current Vs Industry Vs History
Cash-To-Debt 1.71
Equity-to-Asset 0.5
Debt-to-Equity 0.78
Debt-to-EBITDA -0.44
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -4.05
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 50.32
9-Day RSI 46.16
14-Day RSI 44.74
6-1 Month Momentum % -45.85
12-1 Month Momentum % -80.78

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.73
Quick Ratio 4.73
Cash Ratio 4.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -126.2

Profitability Rank

Name Current Vs Industry Vs History
ROE % -131.87
ROA % -71.86
ROIC % -189.74
ROC (Joel Greenblatt) % -826.28
ROCE % -77.45

Financials (Next Earnings Date:2022-08-03 Est.)

XFOR's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:XFOR

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -3.46
Beta 0.23
Volatility % 56.63
14-Day RSI 44.74
14-Day ATR ($) 0.130957
20-Day SMA ($) 1.10575
12-1 Month Momentum % -80.78
52-Week Range ($) 0.861 - 6.68
Shares Outstanding (Mil) 30.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

X4 Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More